WO2006050544A3 - Tolperison zur behandlung von hunden mit degenerativen, spinalen symptomen - Google Patents

Tolperison zur behandlung von hunden mit degenerativen, spinalen symptomen Download PDF

Info

Publication number
WO2006050544A3
WO2006050544A3 PCT/AT2005/000382 AT2005000382W WO2006050544A3 WO 2006050544 A3 WO2006050544 A3 WO 2006050544A3 AT 2005000382 W AT2005000382 W AT 2005000382W WO 2006050544 A3 WO2006050544 A3 WO 2006050544A3
Authority
WO
WIPO (PCT)
Prior art keywords
tolperison
degenerative spinal
preparation
tolpersion
dogs
Prior art date
Application number
PCT/AT2005/000382
Other languages
English (en)
French (fr)
Other versions
WO2006050544A2 (de
Inventor
Angelika Bodenteich
Werner J Frantsits
Josef Boeckmann
Robert Verner
Original Assignee
Sanochemia Pharmazeutika Ag
Angelika Bodenteich
Werner J Frantsits
Josef Boeckmann
Robert Verner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag, Angelika Bodenteich, Werner J Frantsits, Josef Boeckmann, Robert Verner filed Critical Sanochemia Pharmazeutika Ag
Publication of WO2006050544A2 publication Critical patent/WO2006050544A2/de
Publication of WO2006050544A3 publication Critical patent/WO2006050544A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Die Erfindung betrifft ein veterinärmedizinisches Präparat zur oralen Verabreichung bei der Behandlung von Säugetieren, wie Hunden mit degenerativen, spinalen Symptomen, welches als Wirkstoff Tolpersion zusammen mit zumindest einem für die Veterinärmedizin üblichen Zusatzstoff enthält. Eine Reihe von Krankheitsbildern in postoperativer Form oder auch bei der Vorbereitung etwaiger chirurgischer Eingriffe oder aber bei einer lang andauernden, ohne etwaige chirurgische Eingriffe vorgesehenen Therapie können insoferne behandelt werden, als Tolperison als Racemat in Form seines Isomerengemisches eingesetzt wird, wobei das R(-)-Isomer in diesem Gemisch angereichert ist.
PCT/AT2005/000382 2004-11-11 2005-09-22 Tolperison zur behandlung von hunden mit degenerativen, spinalen symptomen WO2006050544A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0188504A AT500999A1 (de) 2004-11-11 2004-11-11 Tolperison enthaltendes veterinärmedizinisches präparat zur oralen verabreichung bei der behandlung von säugetieren, wie hunden mit degenerativen, spinalen symptomen
ATA1885/2004 2004-11-11

Publications (2)

Publication Number Publication Date
WO2006050544A2 WO2006050544A2 (de) 2006-05-18
WO2006050544A3 true WO2006050544A3 (de) 2006-08-10

Family

ID=36123134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2005/000382 WO2006050544A2 (de) 2004-11-11 2005-09-22 Tolperison zur behandlung von hunden mit degenerativen, spinalen symptomen

Country Status (2)

Country Link
AT (1) AT500999A1 (de)
WO (1) WO2006050544A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039576A1 (de) * 2003-10-23 2005-05-06 Meda Pharma Gmbh & Co. Kg Kombinationen aus kaliumkanalöffnern und natriumkanalinhibitoren oder natriumkanal beeinflussenden wirkstoffen zur behandlung von schmerzzuständen
WO2005084676A1 (de) * 2004-03-05 2005-09-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039576A1 (de) * 2003-10-23 2005-05-06 Meda Pharma Gmbh & Co. Kg Kombinationen aus kaliumkanalöffnern und natriumkanalinhibitoren oder natriumkanal beeinflussenden wirkstoffen zur behandlung von schmerzzuständen
WO2005084676A1 (de) * 2004-03-05 2005-09-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FURUTA Y ET AL: "Reversible adrenergic alpha-receptor blocking action of 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone).", JAPANESE JOURNAL OF PHARMACOLOGY. OCT 1976, vol. 26, no. 5, October 1976 (1976-10-01), pages 543 - 550, XP008062968, ISSN: 0021-5198 *
KISS A M ET AL: "Observations with high-dose Mydocalm therapy.", THERAPIA HUNGARICA (ENGLISH EDITION) 1993, vol. 41, no. 2, 1993, pages 51 - 54, XP008062961, ISSN: 0133-3909 *
KONRÁD K: "Adjuvant effect of oral Mydocalm treatment with massive doses in locomotor disease patients.", THERAPIA HUNGARICA (ENGLISH EDITION) 1987, vol. 35, no. 3, 1987, pages 152 - 155, XP008062960, ISSN: 0133-3909 *
PRATZEL H G ET AL: "Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial.", PAIN. OCT 1996, vol. 67, no. 2-3, October 1996 (1996-10-01), pages 417 - 425, XP008062953, ISSN: 0304-3959 *
YOKOYAMA T ET AL: "Determination of tolperisone enantiomers in plasma and their disposition in rats.", CHEMICAL & PHARMACEUTICAL BULLETIN. JAN 1992, vol. 40, no. 1, January 1992 (1992-01-01), pages 272 - 274, XP008063601, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
WO2006050544A2 (de) 2006-05-18
AT500999A1 (de) 2006-05-15

Similar Documents

Publication Publication Date Title
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
WO2003061567A3 (en) Selective s1p1/edg1 receptor agonists
EP1784388B8 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
EP2305640A3 (de) Substituierte Diphenyl-Ether, -Amine, -Sulfide und -Methane zur Behandlung von Beschwerden der Atemwege
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2004099192A3 (en) Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2004099170A3 (en) Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
BRPI0511327A (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
EA200501710A1 (ru) Замещённые карбоновые кислоты
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
EA200501715A1 (ru) Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
TW200611694A (en) Liquid composition for veterinary medicine, process for its preparation and use thereof
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
EP1637132A4 (de) Externes präparat zur behandlung von fussflechte
WO2007035573A3 (en) Anesthesia induction and maintenance drug
EA200701615A1 (ru) Новые лекарственные средства для лечения заболеваний дыхательных путей
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
ID29025A (id) Fenilalkenoilguanidina-fenilalkenoilguanidina yang disubstitusi asam empedu, proses pembuatannya, penggunaannya sebagai obat atau diaknostik dan obat-obat yang mengandungnya
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 05784442

Country of ref document: EP

Kind code of ref document: A2